SCHEMBL30714591

SCHEMBL30714591

Cn1nc2ccc(OCc3ccccn3)cc2c1C(=O)NC(C)(CO)C(N)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.41
SMO Q99835 5/20 0.39
MAPK14 Q16539 4/20 0.39
PDE5A O76074 6/20 0.38
PDE4A P27815 6/20 0.38
PDE4B Q07343 6/20 0.38
PDE4C Q08493 6/20 0.38
PDE4D Q08499 6/20 0.38
CYP2C9 P11712 3/20 0.38
CYP3A4 P08684 2/20 0.38
TSHR P16473 1/20 0.38
ALOX12 P18054 1/20 0.38
NFKB1 P19838 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PDE3B Q13370 2/20 0.37
PDE3A Q14432 2/20 0.37
KCNH2 Q12809 1/20 0.37
ALOX5 P09917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26868963 0.92 SMO (0.40) PARP10SMOMAPK14PDE5APDE4A
SCHEMBL26875249 0.90 PARP10 (0.40) PARP10PDE5APDE4APDE4BPDE4C
SCHEMBL30714664 0.89 SMO (0.41) PARP10SMOMAPK14PDE5APDE4A
SCHEMBL30714627 0.88 PARP10 (0.40) PARP10SMOMAPK14PDE5APDE4A
SCHEMBL30714551 0.87 ALOX5AP (0.39) CYP2C9CYP3A4ALOX5AP
SCHEMBL30714690 0.87 ALOX5AP (0.40) ALOX5AP
SCHEMBL26868969 0.86 PARP10 (0.38) PARP10SMOMAPK14PDE5APDE4A
SCHEMBL30714556 0.85 PARP15 (0.42) PARP10NFKB1KCNH2
SCHEMBL30714726 0.85 SMO (0.39) PARP10SMOMAPK14PDE5APDE4A
SCHEMBL26869163 0.85 SMO (0.39) PARP10SMOMAPK14PDE5APDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 PARP10 1863/4885SMO 3806/4885MAPK14 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.